Biogen’s salanersen gains FDA breakthrough therapy designation for SMA

Pharmaceutical Business Review

This advance recognises preliminary data indicating that salanersen may show substantial improvement over existing therapies for SMA.

pharminent June 5, 2026 (Last updated: June 5, 2026)

Pharmaceutical Business Review

This advance recognises preliminary data indicating that salanersen may show substantial improvement over existing therapies for SMA.

Related Stories